Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis.

ABSTRACT:

Background

Animal studies reporting immune checkpoint inhibitors (CPIs) improved host defense and survival during bacterial sepsis provided one basis for phase I CPI sepsis trials. We performed a systematic review and meta-analysis examining the benefit of CPI therapy in preclinical studies, and whether variables potentially altering this clinical benefit were investigated. Studies were analyzed that compared survival following bacteria or lipopolysaccharide challenge in animals treated with inhibitors to programmed death-1 (PD-1), PD-ligand1 (PD-L1), cytotoxic T lymphocyte-associated protein-4 (CTLA-4), or B- and T-lymphocyte attenuator (BTLA) versus control.

Results

Nineteen experiments from 11 studies (n = 709) were included. All experiments were in mice, and 10 of the 19

SUBMITTER: Busch LM 

PROVIDER: S-EPMC7000606 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature